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ABSTRACT
Bisphosphonates are the primary therapy for postmenopausal and glucocorticoid-induced osteoporosis. Case series suggest a potential
link between prolonged use of bisphosphonates and low-energy fracture of subtrochanteric or diaphyseal femur as a consequence of
oversuppression of bone resorption. Using health care utilization data, we conducted a propensity score–matched cohort study to
examine the incidence rates (IRs) and risk of subtrochanteric or diaphyseal femur fractures among oral bisphosphonate users compared
with raloxifene or calcitonin users. A Cox proportional hazards model evaluated the risk of these fractures associated with duration of
osteoporosis treatment. A total of 104 subtrochanteric or diaphyseal femur fractures were observed among 33,815 patients. The
estimated IR of subtrochanteric or diaphyseal femur fractures per 1000 person-years was 1.46 [95% confidence interval (CI) 1.11–1.88]
among the bisphosphonate users and 1.43 (95% CI 1.06–1.89) among raloxifene/calcitonin users. No significant association between
bisphosphonate use and subtrochanteric or diaphyseal femur fractures was found [hazard ratio (HR)¼1.03, 95% CI 0.70–1.52] compared
with raloxifene/calcitonin. Even with this large study size, we had little precision in estimating the risk of subtrochanteric or diaphyseal
femur fractures in patients treated with bisphosphonates for longer than 5 years (HR¼2.02, 95% CI 0.41–10.00). The occurrence of
subtrochanteric ordiaphysealfemur fracturewasrare.Therewasnoevidenceofanincreasedriskofsubtrochanteric ordiaphysealfemur
fractures in bisphosphonate users compared with raloxifene/calcitonin users. However, this study cannot exclude the possibility that
long-term bisphosphonate use may increase the risk of these fractures.  2011 American Society for Bone and Mineral Research.
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Introduction
B
isphosphonates decrease bone turnover and increase bone
mineral density (BMD) by inhibiting osteoclast-mediated
bone resorption.
(1) Because of their clinical efficacy in reducing
the risk of fractures in patients with osteopenia or osteoporosis,
bisphosphonates have been used widely for the prevention and
treatment of osteoporosis.
(1,2) Over the past few years, a number
of case series have suggested a potential association between
low-energy atypical fracture of the femur and bisphosphonates
use.
(3–11) It is thought that long-term treatment with bispho-
sphonates may result in adynamic brittle bone, leading to
atypical fractures, usually defined as subtrochanteric or
diaphyseal femur fractures after minimal or no trauma.
(8,12)
Characteristic radiographic patterns of these fractures include
bilateral cortical thickening and a transverse or oblique ( 30
degrees) fracture with a beaking of the cortex.
(6,13)
A case series from Sweden estimated that the crude incidence
of stress fractures of the femoral shaft in bisphosphonate users
was 1 per 1000 person-years, 50 times higher than that for the
untreated women.
(11) However, these estimates were based on
a small number of patients, a short follow-up duration, and
uncertain denominators.
ADanishcohortstudyof15,561patientswithbaselinefracture
reported that the hazard ratio (HR) was 1.46 [95% confidence
interval (CI) 0.91–2.35] for subtrochanteric or diaphyseal femur
fracture and 1.45 (95% CI 1.21–1.74) for classic osteoporotic hip
fracture in alendronate users compared with no osteoporosis
treatment.
(14) The authors suggested that subtrochanteric or
diaphyseal femur fractures were more likely related to
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993osteoporosis than to alendronate use.
(14) The results of the study
should be interpreted with caution because the patients were
not allocated randomly to the two groups, alendronate or no
treatment. In the observational setting, there is always a reason
why some patients received a prescription and some did
not.
(15–17) Therefore, the outcomes of the patient groups would
not be comparable, and the validity of any inferences drawn
about the relative effects of treatment would be subject to
unmeasured confounding (ie, confounding by indica-
tion).
(15,17,18) Data from recent secondary analyses using three
large placebo-controlled, randomized clinical trials (RCTs) of
bisphosphonates showed that the occurrence of atypical
subtrochanteric or diaphyseal femoral fracture was rare among
14,195 women (0.23 per 1000 person-years).
(19) Of those, 3673
were treated with alendronate and 3875 with intravenous
zoledronic acid. The HRs for bisphosphonate use compared with
placebo ranged from 1.03 to 1.50 with wide 95% CIs including
the null value of 1 owing to the small number of outcomes.
Furthermore, the generalizability of the results from clinical trials
may be limited.
(19) In March 2010, the US Food and Drug
Administration (FDA) issued a safety announcement that there
was no clear connection between bisphosphonate use and risk
of atypical femur fractures in their ongoing review.
(20)
Given the limitations in the currently available data, we
conducted a large population-based cohort study (1) to estimate
the incidence rates (IRs) and HRs of subtrochanteric and
diaphyseal femoral fractures in elderly patients treated with
oral bisphosphonates compared with those treated with either
raloxifene or calcitonin nasal spray and (2) to examine the
potential risk of these fractures associated with treatment
duration. To control confounding by indication to a large extent,
we used the propensity score–matching method embedded in a
new user cohort design comparing two active treatments. A
propensity score isthe estimated probability of starting treatment
A versus starting treatment B based on preexisting patient
characteristics.
(17,21) Propensity score matching has been used
increasingly as an effective way to adjust a large number of
confounders simultaneously, even if the outcome is rare.
(17,18)
Methods
Data source and study patients
A large cohort study was conducted using health care utilization
databases fromtwoUS states:(1)Medicarebeneficiariesenrolled
in the Pharmaceutical Assistance Contract for the Elderly in
Pennsylvania fromJanuary 1996through December2006and(2)
Medicare beneficiaries enrolled in the Pharmaceutical Assistance
to the Aged and Disabled in New Jersey from January 1996
through December 2006. Both drug benefits programs provided
comprehensive pharmacy coverage with a small or no
copayment for the low-income elderly.
We identified subjects who had at least one prescription filled
for osteoporosis treatment (ie, oral bisphosphonates, raloxifene,
or calcitonin nasal spray) and at least one medical claim during
each of three consecutive 6-month periods before the first use
of osteoporosis treatment. These criteria ensured their contin-
uous eligibility for at least one year prior to study entry to permit
us to identify new users of osteoporosis drugs and to assess
their comorbidities and other medications. Propensity score–
matching methods then were used to select a subset of oral
bisphosphonate usersandacombined group ofeitherraloxifene
or calcitonin nasal spray users who were compatible with regard
to the potential confounders described below (see Table 1 for
the variables included in the propensity score calculation).
(22)
Drug exposures
We compared new users of oral bisphosphonate with new users
of either raloxifene or calcitonin nasal spray. Oral bispho-
sphonates included in the study were alendronate, risedronate,
and etidronate. Ibandronate was not available during the study
period. Switchers between different oral bisphosphonate agents
were considered as continuous users unless there was a gap
between two bisphosphonate drug prescriptions of longer than
90 days.
For both the primary (‘‘as treated’’) and secondary (‘‘first
exposure carried forward’’) analyses, in which a lag period of
90 days was required, follow-up began 91 days after filling the
first prescription of either exposures of interest. The second
prescription fillforthesameexposuregroupwasrequiredduring
the 90-day lag period (Fig. 1).
For the primary analysis, subjects were followed up until
90 days after the last drug available date, assuming that
bisphosphonates have a long duration of action. Last drug
available date was calculated as the number of days of supply
after the last prescription fill date. For the secondary analysis,
mimicking an intention-to-treat analysis used in clinical trials,
subjects were followed up for 365 days and considered ‘‘always
exposed’’ on the basis of the first exposure regardless of drug
discontinuation or switching drug during the follow-up period.
We also performed a sensitivity analysis (‘‘as treated with no
lag period’’), in which the follow-up started at the date of the first
prescription fill and continued until 90 days after the last drug
available date (Fig. 1).
Outcomes
We used definitions of subtrochanteric (ICD-9 820.22) and
diaphyseal (ICD-9 821.0x) femur fracture based on primary
hospital discharge diagnosis codes. In a recent validation
study, administrative claims–based algorithms using the
primary hospital discharge diagnosis codes to identify cases
of subtrochanteric or diaphyseal femur fracture yielded high
positive predictive values between 0.75 and 0.86.
(23) The primary
outcome of interest was a combined endpoint of subtrochan-
teric and diaphyseal femur fractures. When a patient had both
subtrochanteric and diaphyseal femur fractures, it was counted
as a single fracture. We also evaluated whether the outcomes
were related to major trauma based on various diagnoses codes
(Supplemental Table S1).
Patients were censored at the earliest time of the following
events during the follow-up period: (1) occurrence of the first
outcome, (2) occurrence of typical hip fracture, defined with ICD
9 820.0-820.1 and 820.8-820.9, (3) admission to a nursing home,
(4) end of study period, or (5) death. Typical hip fractures were
considered censoring events because most patients with hip
994 Journal of Bone and Mineral Research KIM ET AL.fractures would undergo surgical repaired
(24) and therefore have
different risks for subsequent fractures of the femur. Owing to
incomplete prescription data among nursing home residents in
the study database, subjects were censored at the time of
nursing home admission. Subjects who did not have any
dispensing during the lag period and who had censoring events
during the lag period were excluded from the analyses.
Covariates
Patient characteristics potentially related to a future femur
fracture were assessed using the data from the 12 months prior
to the first prescription fill date. These characteristics included
demographic factors (eg, age, sex, race, and state), calendar year,
nursing home resident, health care utilization factors (eg, acute-
care hospitalizations, emergency room visits, and number of
physician visits and different medications), other recorded
comorbidities (eg, prior falls, prior hip or vertebral fractures, BMD
test, alcoholism, Parkinson disease, dementia, chronic kidney or
liverdisease,hypertension, diabetesmellitus,chronicobstructive
pulmonary disease, heart failure, inflammatory arthritis, and
inflammatory bowel disease), and use of other medications likely
associated with bone metabolism or fall risks (eg, oral or inhaled
glucocorticoids, anticonvulsants, benzodiazepines, selective
Table 1. Characteristics of Propensity Score–Matched Study Population in 12 Months Prior to Filling Their First Osteoporosis Drug
Prescription
Bisphosphonates Raloxifene/calcitonin
n 17,028 16,787
Demographic factors
Age, years, mean (SD) 79.9 (6.5) 80.0 (6.9)
Race, white 16,180 (95) 15,987 (95.2)
Sex, female 16,474 (96.8) 16,244 (96.8)
Health care utilization
No. of visits, mean (SD) 10.6 (6) 10.5 (6.1)
ER visit 4,505 (26.5) 4,482 (26.7)
No. of all prescription drugs, mean (SD) 10.4 (6) 10.5 (6.1)
Hospitalization 6,089 (35.8) 6,146 (36.6)
Nursing home resident 1,882 (11.1) 1,991 (11.9)
Comorbidities
Prior fall 2,094 (12.3) 2,119 (12.6)
Prior hip fracture 612 (3.6) 601 (3.6)
Prior vertebral fracture 1,858 (10.9) 1,890 (11.3)
BMD test 4,085 (24) 4,180 (24.9)
Hypertension 11,303 (66.4) 11,233 (66.9)
Chronic kidney disease 492 (2.9) 481 (2.9)
Chronic liver disease 207 (1.2) 191 (1.1)
Parkinson disease 586 (3.4) 598 (3.6)
Dementia 1,039 (6.1) 1,092 (6.5)
Diabetes mellitus 4,354 (25.6) 4,312 (25.7)
Congestive heart failure 3,664 (21.5) 3,728 (22.2)
Chronic obstructive pulmonary disease (COPD) 4,782 (28.1) 4,763 (28.4)
Inflammatory arthritis 1,267 (7.4) 1,258 (7.5)
Inflammatory bowel disease 241 (1.4) 226 (1.4)
Alcoholism 311 (1.8) 301 (1.8)
Comorbidity index, mean (SD) 1.9 (1.9) 2 (1.9)
Other medications
Opioids 6,817 (40) 6,826 (40.7)
Antiepileptics 892 (5.2) 877 (5.2)
Proton pump inhibitors 4,361 (25.6) 4,441 (26.5)
Benzodiazepines 4,636 (27.2) 4,614 (27.5)
Selective serotonin reuptake inhibitors (SSRIs) 2,654 (15.6) 2,683 (16)
Warfarin 1,814 (10.7) 1,786 (10.6)
Inhaled steroid 1,389 (8.2) 1,391 (8.3)
Oral steroid 2,420 (14.2) 2,387 (14.2)
Note: New Jersey and Pennsylvania combined, second drug dispensing and a 90-day lag period are required. Data are presented in number (%), unless
specified.
SD¼standard deviation; ER¼emergency room; BMD¼bone mineral density.
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pump inhibitors, and opioids).
To quantify patients’ comorbidities, we additionally calculated
the Deyo-adapted Charlson Comorbidity Index based on ICD-9-
CM for the 12 months prior to the first prescription fill date.
(25,26)
The Charlson Comorbidity Index is a summary score based on 19
major medical conditions, including myocardial infarction;
pulmonary, renal, or hepatic disease; diabetes; cancer; human
immunodeficiency virus infection; and so on. A score of 0
represents absence of comorbidity, and a higher score indicates
a greater number of comorbid conditions. Duration of treatment
with either oral bisphosphonates or raloxifene/calcitonin was
assessed for subgroup analysis.
Statistical analysis
Logistic regression models were developed to calculate the
propensity score of individual patients in each state, Pennsylva-
nia or New Jersey. The propensity score is the probability of
initiating oral bisphosphonates versus either raloxifene or
calcitonin nasal spray as a function of all the potential
confounders listed in Table 1 and calendar year. Propensity
scores were calculated at their first prescription fill date. Patients
in each group (oral bisphosphonates versus raloxifene/calcito-
nin) then were matched 1:1 with the second decimal place of the
estimated propensity scores. After the propensity score match-
ing, subjects from the two stateswere pooled forall the analyses.
Fig. 1. Study design. Subjects were required to have at least one claim each during the prior three 6-month intervals. For both the primary (‘‘as treated’’)
and secondary (‘‘first exposure carried forward’’) analyses, follow-up began on the 91st day after filling the first prescription of either exposure of interest.
The second prescription fill for the same exposure drug group was required during the 90-day lag period. For the primary analysis (A), we continued the
follow-upuntil 90days afterthelast drugavailabledate.Last drugavailable datewascalculatedwith a numberof days ofsupply afterthelast prescription
fill date. For thesecondary analysis(B), thefollow-upcontinueduntil 365days afterthe indexdate. Patientswereconsidered‘‘alwaysexposed’’for thefirst
exposure drug group during the follow-up period. In a sensitivity analysis (C), follow-up began at the first prescription fill and ended 90 days after the last
drug available date.
Fig. 2. Flow diagram of cohort selection. PACE¼Pennsylvania Pharmaceutical Assistance Contract for the Elderly; PAAD¼New Jersey Pharmaceutical
Assistance to the Aged and Disabled.
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before and after the propensity score matching.
The IRs of subtrochanteric and diaphyseal fractures were
calculated among propensity score–matched patients in each
treatment group. Cox proportional hazard analyses were used to
estimatetheHRsandthe95%CIsoftheriskofsubtrochantericor
diaphyseal femur fractures among oral bisphosphonate users
compared with raloxifene/calcitonin users. Since we matched
the groups on propensity scores containing potential con-
founders, the Cox regression models contained only a variable
for the exposures of interest, with raloxifene/calcitonin as the
reference exposure. We tested the proportional hazards
assumption for each exposure of interest with respect to each
of the fracture outcomes via the Kolmogorov supremum test.
(27)
We also constructed adjusted Kaplan-Meier fracture-free survival
curves and inspected two-way log-rank tests. A Cox model
stratified by treatment duration (<1 year, 1 to 2 years, 3 to 4
years, and 4 years or more) was used to assess the association
between the risk of fracture and duration of treatment. All
analyses were conducted using SAS Statistical Software Version
9.2 (SAS Institute, Inc., Cary, NC, USA).
This work was approved by the Brigham and Women’s
Hospital’s Institutional Review Board. Data-use agreements were
in place with Medicare and the state pharmacy benefit programs
that supplied information for the study database. All potentially
traceable personal identifiers were removed from the data
before analyses to protect patient privacy.
Results
Cohort selection
Figure 2 illustrates our cohort selection process for the primary
and secondary analyses. Of 89,906 new users of oral bispho-
sphonates, raloxifene, or calcitonin nasal spray with at least one
claim each during the prior three 6-month intervals, 59,897
subjects had at least two consecutive prescription fills. After 1:1
propensityscorematching,atotalof37,030subjectswithatleast
two prescription fills for osteoporosis drugs were identified. We
excluded 3215 patients who had a censoring event during the
90-day lag period. Our final cohort consisted of 17,028 oral
bisphosphonate users and 16,787 raloxifene/calcitonin users.
For the sensitivity analysis, a total of 59,642 subjects with at
least one prescription fill for osteoporosis drugs were identified
after 1:1 propensity score matching.
Patient characteristics
The baseline characteristics of propensity score–matched
patients with at least two prescription fills are listed in
Table 1. The mean age was 79.9 years (SD 6.5) in bisphosphonate
users and 80.0 years (SD 6.9) in raloxifene/calcitonin users.
Ninety-seven percent were women and 95% were white in both
groups. A mean duration of follow-up was 2.13 years (SD 2.21);
however, more than 4000 patients had a follow-up longer than 5
years. Approximately 84% of the subjects in the bisphosphonate
group were treated with alendronate, 14% with risedronate, and
2% with etidronate. Seventy-two percent of the subjects in the
raloxifene/calcitonin group were treated with calcitonin. The
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utilization patterns, comorbidities, and use of other medications
than the unmatched cohorts (Supplemental Table S1).
Subtrochanteric or diaphyseal femur fractures
A total of 104 subtrochanteric or diaphyseal femur fractures was
observed for our primary analysis. Only two major trauma-
related fractures in the propensity score–matched cohorts were
noted and excluded from the analysis. Incidence rates for
subtrochanteric or diaphyseal femur fracture were calculated in
the propensity score–matched cohorts (Table 2). The primary
analysis estimated that there were 1.46 subtrochanteric or
diaphyseal femur fractures (0.92 subtrochanteric and 0.61
diaphyseal) per 1000 person-years among the bisphosphonate
users. The IRs were similar among raloxifene/calcitonin users.
Similar IRs across both groups were noted in both the secondary
and sensitivity analyses (Table 2).
HRs for each fracture event were estimated with Cox
regression models in the propensity score–matched cohorts
(Table 3). In the primary analysis, oral bisphosphonates were not
associated with a significantly increased risk of subtrochanteric
or diaphyseal (HR¼1.03, 95% CI 0.70–1.52), subtrochanteric
(HR¼0.90, 95% CI 0.56–1.44), or diaphyseal femur fractures
(HR¼1.57, 95% CI 0.80–3.09) compared with raloxifene/
calcitonin. However, owing to the wide confidence interval with
a relatively small number of events, we cannot exclude an
increased risk for diaphyseal fractures of the femur associated
with use of oral bisphosphonates. Similar results were observed
in both the secondary and sensitivity analyses. For every model,
the result of the Kolmogorov-type supremum test was not
significant (all p values>.50). Therefore, the proportional-
hazards assumption was not violated in our models. Figure 3
displays the Kaplan-Meier fracture-free survival curves over the
follow-up period for the primary analysis. The rates of
subtrochanteric or diaphyseal femur fractures did not differ
meaningfully among the two groups.
Overall, no significant differences were noted between the
two groups for the risk of subtrochanteric or diaphyseal fracture
of the femur stratified by treatment duration (Fig. 4), although
the HR was 2.02 with a wide confidence interval (95% CI 0.41–
10.00) among those treated for longer than 5 years (2371
bisphosphonate users compared with 1726 raloxifene/calcitonin
users).
Discussion
Bisphosphonates are used widely for the prevention and
treatment of osteopenia and osteoporosis. Common side effects
such as heartburn, esophageal irritation, and musculoskeletal
pain are well known, whereas few data, particularly from
prospective studies with a long-term follow-up, exist on the
questionable association between atypical femur fractures and
the use of bisphosphonates.
(13,28) In this large propensity score–
matched cohort study using health care utilization data, there
was no difference in the risk of subtrochanteric or diaphyseal
femur fractures in bisphosphonate users compared with
raloxifene/calcitonin users. Occurrence of these fractures among
both bisphosphonate and raloxifene/calcitonin users was rare in
this study.
The estimated IR of subtrochanteric or diaphyseal femur
fractures was 1.46 per 1000 person-years among bispho-
sphonate users and 1.43 per 1000 person-years among
raloxifene/calcitonin users. The results of the primary analysis
(HR¼1.03, 95% CI 0.70–1.52) indicate that an increase in the rate
of subtrochanteric or diaphyseal femur fracture associated with
oral bisphosphonate uses by more than 0.74 per 1000 person-
years can be excluded with a confidence level of 95%.
(29)
Our study has several important implications. We compared
the risk of subtrochanteric or diaphyseal femur fracture between
two active osteoporosis treatment groups with the propensity
score–matching method to minimize confounding by indication.
In addition, we used multiple approaches in study design and
analysis and obtained consistent results. Our results on the IRs of
subtrochantericordiaphysealfemurfracturesaresimilartothose
from the Danish cohort study
(14) but somewhat higher than the
results (0.25 per 1000 person-years) from two recent stu-
dies.
(19,30) Although the IRs in our study may have been
Table 3. Hazard Ratios (95% CIs) for Subtrochanteric or Diaphyseal Femur Fracture in the Propensity Score–Matched Population
Fractures Bisphosphonates Raloxifene/calcitonin
Primary (as treated) analysis
Subtrochanteric or diaphyseal femur fracture 1.03 (0.70–1.52) 1.00
Subtrochanteric femur fracture 0.90 (0.56–1.44) 1.00
Diaphyseal femur fracture 1.57 (0.80–3.09) 1.00
Secondary (first exposure carried forward) analysis
Subtrochanteric or diaphyseal femur fracture 1.02 (0.56–1.85) 1.00
Subtrochanteric femur fracture 0.91 (0.45–1.84) 1.00
Diaphyseal fracture 1.55 (0.51–4.75) 1.00
Sensitivity (as treated with no lag period) analysis
Subtrochanteric or diaphyseal femur fracture 0.91 (0.66–1.26) 1.00
Subtrochanteric femur fracture 0.74 (0.48–1.12) 1.00
Diaphyseal femur fracture 1.41 (0.87–2.27) 1.00
998 Journal of Bone and Mineral Research KIM ET AL.overestimated because we could not assess whether all the
subtrochanteric or diaphyseal femur fractures in our study had
characteristic radiographic findings of atypical fracture, such as a
simple transverse fracture with cortical thickening,
(6) morpho-
logic evaluation of fractures with radiographs were not done in
twootherpreviousstudies
(14,30)andareavailableonlyinasubset
of subjects in the secondary analyses of three RCTs.
(19) Therefore,
the differences in these rates probably are related to the
characteristics of our study population [ie, study size, mostly
female (>95%), users of osteoporosis drugs, low socioeconomic
status, and a greater number of medical comorbidities and
prescription drugs].
Several case series suggested a risk of atypical femur fracture
particularly with long-term use of bisphosphonates.
(3,6,7,9) In our
subgroup analysis of 4097 patients, the relative hazard
associated with long-term use of bisphosphonates (>5 years)
compared with raloxifene/calcitonin use was 2.02 (95% CI 0.41–
10.00). Similar results were noted in two earlier studies, although
bothstudieswerebasedonamuchsmallernumberoflong-term
users and outcomes. There were only five subtrochanteric or
diaphysealfemurfractures among178patientswithalendronate
use for longer than 6 years in the Danish cohort study (HR¼1.37,
95% CI 0.22–8.62)
(14) and two atypical subtrochanteric or
diaphysealfemurfractures among662patientswithalendronate
use for longer than 5 years in the Fracture Intervention Trial (FIT)
Long-Term Extension trial (HR¼1.33, 95% CI 0.12–14.67).
(19)
Studies that did not observe statistically significant changes
merit special attention to their statistical power to detect a
clinically meaningful change.
(31) Even though we conducted a
large-scale cohort study, it is still possible that we did not have
sufficientpowertodetecttheexcessriskforsucharareoutcome.
In a study by Black and colleagues,
(19) the number needed to
treat with a bisphosphonate to observe one excess atypical
femur fracture was 725 based on a hypothetical relative risk of
3.0 compared with placebo. We estimated that 450 patients
wouldneed tobetreated withabisphosphonate formore than 5
years to observe one excess subtrochanteric or diaphyseal femur
fracture, assuming a hypothetical relative risk of 3.0, compared
with those treated with raloxifene or calcitonin. Given the results
from the FIT, which showed that treating 81 postmenopausal
women with osteoporosis with alendronate for over 4 years
would prevent one hip fracture,
(32) the benefit clearly outweighs
the risk, even with such a high hypothetical risk.
Confounding bias is the major barrier to using large
administrative claims databases for pharmacoepidemiologic
research. One could avoid the issue of confounding bias by
conducting a RCT.
(15) However, there are a number of important
limitations in RCTs to study long-term safety of drugs, such as
insufficient sample sizes, inadequate duration of follow-up,
generalizability, ethical issues, and substantial cost. We therefore
conducted a large population-based cohort study and
attempted to minimize this bias by selecting new users of
osteoporosis drugs and matching them based on a propensity
score that included many potentially important confounders,
resulting in well-balanced cohorts with respect to the measured
variables in the database. However, it is possible that differences
still exist between the groups, resulting in residual confounding
owing to unmeasured confounders (eg, calcium and vitamin D
intake, BMD, body mass index, and frailty) not included in the
propensity score calculation. We included both female and male
patients in this study, although the majority of patients (97%)
were female. Five hundred and forty male patients in the
raloxifene/calcitonin group were calcitonin users because
raloxifene is indicated only in female patients.
Fig. 3. Kaplan-Meier curves for fracture-free survival in oral bisphospho-
nates versus raloxifene/calcitonin nasal spray.
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of exposures and outcomes. While we used pharmacy claims
data, which are considered to be one of the best data sources for
drug exposure, to identify the exposure in this study,
(33) actual
patient adherence to the medication is unknown. The outcomes
in this study were identified by the diagnosis codes from
administrative claims. Although the accuracy of the specific
codes used in this study has been validated recently in other
claims data,
(23) we could not verify diagnoses of subtrochanteric
or diaphyseal femur fracture based on specific radiographic
characteristics in the study database. However, the impact of this
misclassification bias is most likely nondifferential between
bisphosphonates and raloxifene/calcitonin users.
In conclusion, we found no significant differences in the risk of
either subtrochanteric or diaphyseal fractures of the femur
between users of oral bisphosphonates and raloxifene/calcitonin
nasal spray. Despite the large study size, however, we still had
little precision in estimating the risk of subtrochanteric or
diaphyseal femur fractures associated with use of bispho-
sphonates for more than 5 years. Thus we cannot rule out the
possibilityofanincreasedriskofthesefemurfracturesassociated
with long-term use of bisphosphonates.
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